Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-19T20:57:20.810Z Has data issue: false hasContentIssue false
  • English
  • Français

Variability in Antifungal and Antiviral Use in Hospitalized Children

Published online by Cambridge University Press:  15 March 2017

Jennifer L. Goldman ,
Rachael K. Ross ,
Brian R. Lee ,
Jason G. Newland ,
Adam L. Hersh ,
Matthew P. Kronman  and
Jeffrey S. Gerber
Jennifer L. Goldman*
Affiliation:
Children’s Mercy Hospitals & Clinic, Kansas City, Missouri
Rachael K. Ross
Affiliation:
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Brian R. Lee
Affiliation:
Children’s Mercy Hospitals & Clinic, Kansas City, Missouri
Jason G. Newland
Affiliation:
St Louis Children’s Hospital, Washington University, St Louis, Missouri
Adam L. Hersh
Affiliation:
Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah
Matthew P. Kronman
Affiliation:
Seattle Children’s Hospital, Seattle, Washington.
Jeffrey S. Gerber
Affiliation:
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
*
Address correspondence to Jennifer Goldman, MD, MS, Department of Pediatrics, Children’s Mercy Hospital, 2401 Gillham Rd., Kansas City, MO 64108 (jlgoldman@cmh.edu).
Get access Rights & Permissions [Opens in a new window]

Abstract

We analyzed antifungal and antiviral prescribing among high-risk children across freestanding children’s hospitals. Antifungal and antiviral days of therapy varied across hospitals. Benchmarking antifungal and antiviral use and developing antimicrobial stewardship strategies to optimize use of these high cost agents is needed.

Infect Control Hosp Epidemiol 2017;38:743–746

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 38 , Issue 6 , June 2017 , pp. 743 - 746
Copyright
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION: This work was presented at IDWeek on October 29, 2016, in New Orleans, Louisiana (abstract #58549).

References

REFERENCES

1. Newland, JG, Gerber, JS, Weissman, SJ, et al. Prevalence and characteristics of antimicrobial stewardship programs at freestanding children’s hospitals in the United States. Infect Control Hosp Epidemiol 2014;35:265–271.Google Scholar
2. Lestner, JM, Versporten, A, Doerholt, K, et al. Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study. Antimicrob Agents Chemother 2015;59:782–789.CrossRefGoogle ScholarPubMed
3. Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.CrossRefGoogle Scholar
4. Prasad, PA, Coffin, SE, Leckerman, KH, Walsh, TJ, Zaoutis, TE. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008;27:1083–1088.CrossRefGoogle ScholarPubMed
5. Fisher, BT, Gerber, JS, Leckerman, KH, et al. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia Lymphoma 2013;54:1633–1639.Google Scholar
6. Ross, RK, Hersh, AL, Kronman, MP, Newland, JG, Gerber, JS. Cost of antimicrobial therapy across US children’s hospitals. Infect Control Hosp Epidemiol 2015;36:1242–1244.CrossRefGoogle ScholarPubMed
7. Valerio, M, Rodriguez-Gonzalez, CG, Munoz, P, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014;69:1993–1999.Google Scholar
8. Freifeld, AG, Bow, EJ, Sepkowitz, KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427–431.Google Scholar
9. Groll, AH, Castagnola, E, Cesaro, S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15:e327–e340.Google Scholar
10. Micallef, C, Aliyu, SH, Santos, R, Brown, NM, Rosembert, D, Enoch, DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother 2015;70:1908–1911.Google Scholar